Although the MYB and MYBL1 fusion oncoproteins emerge as attractive diagnostic markers and therapeutic targets to improve clinical management of this lethal disease, the manner by which these and other genetic alterations initiate and drive ACC progression is not yet fully understood, and their impact on clinical outcomes remains to be delineated. This evidence concerns the gene MYBL1 and adrenal cortex carcinoma.